09:36 AM EST - Psyched Wellness Ltd. : Announced the company has signed an additional agreement with its CRO partner, KGK Science to further study the anti-inflammatory nature of AME-1. KGK Science specializes in nutraceutical product testing and development and is leading the pre-clinical trials for Psyched. This new agreement will further advance the preliminary findings indicating an anti-inflammatory property of the AME-1 extract. This study will be the first to further explore the anti-inflammatory nature of the AME-1 extract from the Amanita Muscaria mushroom with a particular focus on gut health. When gut health is damaged, it can lead to inflammation thus promoting a chronic condition of the gut lining and impairment of barrier function of the digestive tract. The aim of the study is to explore the anti-inflammatory properties of AME-1 extract and demonstrate activities that may enhance digestive barrier function and immunity. This is significant as gut health and immunity promotion is substantial for health and wellness. "This is a key first step in the health and wellness studies of AME-1, which lay the groundwork for future preclinical research," said Brian Tancowny, scientific advisor to Psyched Wellness. Psyched Wellness Ltd.
shares C.PSYC are trading off 5.08 percent at $0.28.
